New drug trial targets deadly recurrent brain tumors
NCT ID NCT02586857
Summary
This study is testing an oral drug called ACP-196 (acalabrutinib) for adults whose aggressive brain cancer, glioblastoma, has returned after one or two prior treatments. The main goal is to see if the drug can shrink tumors and is safe for patients. It is an early-phase trial for a condition with very limited treatment options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site
Los Angeles, California, 90095-1769, United States
-
Research Site
Palo Alto, California, 94304, United States
-
Research Site
Boston, Massachusetts, 02114, United States
-
Research Site
Boston, Massachusetts, 02215, United States
-
Research Site
Boston, Massachusetts, 2215, United States
-
Research Site
New York, New York, 10021, United States
-
Research Site
Vancouver, Washington, 98684, United States
Conditions
Explore the condition pages connected to this study.